603309 Well Lead Medical
- 12.61
- +0.03+0.24%
Well Lead Medical News
Weili Medical (603309.SH) 2023 equity distribution: 0.5 yuan per share, share registration date May 22
Weili Medical (603309.SH) issued an announcement. The company's 2023 equity distribution will be implemented: each share disbursement discovered...
Well Lead Medical Co., Ltd. (SHSE:603309) Surges 25% Yet Its Low P/E Is No Reason For Excitement
The Well Lead Medical Co., Ltd. (SHSE:603309) share price has done very well over the last month, posting an excellent gain of 25%. Not all shareholders will be feeling jubilant, since the share pr
KARL STORZ and Well Lead Medical Announce Exclusive Agreement for Distribution of ClearPetra Stone-Removal System in the U.S.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction w
Solid Earnings May Not Tell The Whole Story For Well Lead Medical (SHSE:603309)
The market for Well Lead Medical Co., Ltd.'s (SHSE:603309) stock was strong after it released a healthy earnings report last week. While the profit numbers were good, our analysis has found some conc
Weili Healthcare (603309): Significant improvement in overseas business and increased profitability
Matters: The company released financial reports. In '23, the company achieved revenue of 1,388 million yuan (+1.79%), net profit to mother of 192 million yuan (+15.56%), deducting non-net profit of 180 million yuan (+23.25%)
Weili Healthcare (603309): Actively explore overseas markets with high dividends to give back to shareholders
Weili Healthcare has released its 2023 annual report. In 2023, the company achieved operating income of 1,388 billion yuan (year-on-year increase of 1.79%); realized net profit of 192 million yuan (year-on-year increase of 15.56%); achieved deductions
Well Lead Medical Co., Ltd. (SHSE:603309) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Well Lead Medical (SHSE:603309) has had a great run on the share market with its stock up by a significant 13% over the last week. But the company's key financial indicators appear to be differing a
Weili Healthcare (603309): 23Q4 performance growth exceeded expectations and accelerated overseas market development
Event: The company released the 2023 annual report and the first quarter report of 2024. The full year of 2023 achieved operating income of 1,388 million yuan (YoY +1.79%) and net profit of 192 million yuan (YoY+1)
Weili Medical (603309): Maintain steady operation and continue to consolidate business
Event Overview The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved revenue of 1,387 billion yuan, an increase of 1.79% over the previous year; net profit to mother was 192 million yuan, an increase of 15.56% over the previous year;
Weili Medical (603309): Medical catheter faucet with continuously advanced products
Key investment points We believe that as a leading domestic medical catheter company, the company also has strong competitiveness in overseas products, and its market position is relatively stable. Since 2020, with the continuous deepening of marketing reforms, the company's profitability and operating capacity
Weili Medical (603309.SH): Net profit increased 15.56% year-on-year in 2023, and plans to pay 10 to 5 yuan
On April 18, Ge Longhui (603309.SH) announced its 2023 annual report. During the reporting period, it achieved operating income of 1,388 billion yuan, an increase of 1.79%; net profit attributable to shareholders of listed companies of 192 million yuan, an increase of 15.56% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 180 million yuan, an increase of 23.25% year on year; and basic earnings per share of 0.66 yuan. The company plans to distribute a cash dividend of 5 yuan (tax included) for every 10 shares to all shareholders.
Well Lead Medical Co., Ltd.'s (SHSE:603309) Market Cap Dropped CN¥381m Last Week; Private Companies Bore the Brunt
Key Insights The considerable ownership by private companies in Well Lead Medical indicates that they collectively have a greater say in management and business strategy A total of 3 investors have
Weili Medical (603309.SH): The 2024 anesthesia line will focus on promoting new products: visual double lumen bronchial intubation and visual double chamber laryngeal mask
Gelonghui, March 15 | Weili Medical (603309.SH) recently said during a survey receiving institutional investors that in 2024, the new products the company's anesthesia line will focus on are visual double lumen bronchial intubation and visual double chamber laryngeal masks; the new products promoted by catheters are BIP alloy-coated antibacterial catheters and disposable household catheters; the new products mainly promoted by exocrine are second-generation clear stone sheaths.
Weili Medical (603309.SH): The company's products are not clearly seasonal
Gelonghui, March 15 | Weili Medical (603309.SH) recently said during a survey reception from institutional investors that the company's products are not clearly seasonal. In normal years, due to the Spring Festival holiday, the company's production capacity and shipment volume were relatively low in the first quarter, and sales accounted for a low share of annual sales revenue. The company's sales revenue generally showed a quarterly upward trend during the year.
Weili Medical (603309.SH): Future plans to continue to increase overseas promotion of its own brands
Gelonghui, March 12 | Weili Medical (603309.SH) recently said during a survey reception from institutional investors that the company used the innovative product Clear Stone Sheath as a breakthrough to promote its own overseas brands, driving a relatively rapid increase in sales of exocrine products in Europe, America and the Middle East. In the future, the company plans to continue to increase overseas promotion of its own brands, further accelerate overseas localization deployment and strengthen the construction of overseas localized sales channels in the form of overseas factories and overseas business companies simultaneously.
Weili Medical (603309.SH): New products to be promoted by the Anesthesia Line in 2024 are visual double lumen bronchial intubation and visual double chamber laryngeal mask
Gelonghui, March 12 | Weili Medical (603309.SH) recently said during a survey receiving institutional investors that in 2024, the new products the company's anesthesia line will focus on are visual double lumen bronchial intubation and visual double chamber laryngeal masks; the new products promoted by catheters are BIP alloy-coated antibacterial catheters and disposable household catheters; the new products mainly promoted by exocrine are second-generation clear stone sheaths.
Weili Healthcare (603309.SH): No plans to ask for celebrity endorsements
Gelonghui, January 26丨Weili Medical (603309.SH) said on the investor interactive platform that the company has no plans to ask for celebrity endorsements.
Returns At Well Lead Medical (SHSE:603309) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that,
Weili Medical (603309): Deepening reforms and assembling domestic medical catheters before starting
Investment logic: The company is a leading domestic medical catheter, with a rich product matrix to open up domestic and foreign markets. The company is deeply involved in the field of medical catheters. Its products cover the needs of many clinical applications such as anesthesia, catheterization, urology, nursing, breathing, hemodialysis, etc., and global medical
Well Lead Medical Wins EU Certification For Two Catheters
Well Lead Medical (SHA:603309) has acquired European Union medical device regulation (MDR) certification for two of its catheter products, opening the doors for continued sales in the EU market. The c
Analysis
Price Target
No Data
